IBDEI3HT ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,58742,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58742,1,3,0)
;;=3^Rosacea,Unspec
;;^UTILITY(U,$J,358.3,58742,1,4,0)
;;=4^L71.9
;;^UTILITY(U,$J,358.3,58742,2)
;;=^5009276
;;^UTILITY(U,$J,358.3,58743,0)
;;=L71.8^^272^2912^18
;;^UTILITY(U,$J,358.3,58743,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58743,1,3,0)
;;=3^Rosacea NEC
;;^UTILITY(U,$J,358.3,58743,1,4,0)
;;=4^L71.8
;;^UTILITY(U,$J,358.3,58743,2)
;;=^5009275
;;^UTILITY(U,$J,358.3,58744,0)
;;=L71.1^^272^2912^17
;;^UTILITY(U,$J,358.3,58744,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58744,1,3,0)
;;=3^Rhinophyma
;;^UTILITY(U,$J,358.3,58744,1,4,0)
;;=4^L71.1
;;^UTILITY(U,$J,358.3,58744,2)
;;=^106083
;;^UTILITY(U,$J,358.3,58745,0)
;;=S05.31XA^^272^2912^13
;;^UTILITY(U,$J,358.3,58745,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58745,1,3,0)
;;=3^Ocular Laceration Right Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
;;^UTILITY(U,$J,358.3,58745,1,4,0)
;;=4^S05.31XA
;;^UTILITY(U,$J,358.3,58745,2)
;;=^5020606
;;^UTILITY(U,$J,358.3,58746,0)
;;=S05.32XA^^272^2912^12
;;^UTILITY(U,$J,358.3,58746,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58746,1,3,0)
;;=3^Ocular Laceration Left Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
;;^UTILITY(U,$J,358.3,58746,1,4,0)
;;=4^S05.32XA
;;^UTILITY(U,$J,358.3,58746,2)
;;=^5020609
;;^UTILITY(U,$J,358.3,58747,0)
;;=Z21.^^272^2912^2
;;^UTILITY(U,$J,358.3,58747,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58747,1,3,0)
;;=3^Asymptomatic HIV Infection Status
;;^UTILITY(U,$J,358.3,58747,1,4,0)
;;=4^Z21.
;;^UTILITY(U,$J,358.3,58747,2)
;;=^5062777
;;^UTILITY(U,$J,358.3,58748,0)
;;=Z83.511^^272^2912^6
;;^UTILITY(U,$J,358.3,58748,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58748,1,3,0)
;;=3^Family Hx of Glaucoma
;;^UTILITY(U,$J,358.3,58748,1,4,0)
;;=4^Z83.511
;;^UTILITY(U,$J,358.3,58748,2)
;;=^5063382
;;^UTILITY(U,$J,358.3,58749,0)
;;=Z83.518^^272^2912^5
;;^UTILITY(U,$J,358.3,58749,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58749,1,3,0)
;;=3^Family Hx of Eye Disorder NEC
;;^UTILITY(U,$J,358.3,58749,1,4,0)
;;=4^Z83.518
;;^UTILITY(U,$J,358.3,58749,2)
;;=^5063383
;;^UTILITY(U,$J,358.3,58750,0)
;;=Z79.899^^272^2912^10
;;^UTILITY(U,$J,358.3,58750,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58750,1,3,0)
;;=3^Long Term Current Drug Therapy NEC
;;^UTILITY(U,$J,358.3,58750,1,4,0)
;;=4^Z79.899
;;^UTILITY(U,$J,358.3,58750,2)
;;=^5063343
;;^UTILITY(U,$J,358.3,58751,0)
;;=Z01.00^^272^2912^4
;;^UTILITY(U,$J,358.3,58751,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58751,1,3,0)
;;=3^Eye/Vision Exam w/o Abnormal Findings
;;^UTILITY(U,$J,358.3,58751,1,4,0)
;;=4^Z01.00
;;^UTILITY(U,$J,358.3,58751,2)
;;=^5062612
;;^UTILITY(U,$J,358.3,58752,0)
;;=Z01.01^^272^2912^3
;;^UTILITY(U,$J,358.3,58752,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58752,1,3,0)
;;=3^Eye/Vision Exam w/ Abnormal Findings
;;^UTILITY(U,$J,358.3,58752,1,4,0)
;;=4^Z01.01
;;^UTILITY(U,$J,358.3,58752,2)
;;=^5062613
;;^UTILITY(U,$J,358.3,58753,0)
;;=E05.90^^272^2912^21
;;^UTILITY(U,$J,358.3,58753,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58753,1,3,0)
;;=3^Thyrotoxicosis,Unspec
;;^UTILITY(U,$J,358.3,58753,1,4,0)
;;=4^E05.90
;;^UTILITY(U,$J,358.3,58753,2)
;;=^5002492
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3HT 3651 printed Dec 13, 2024@02:49:03 Page 2
IBDEI3HT ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,58742,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,58742,1,3,0)
+4 ;;=3^Rosacea,Unspec
+5 ;;^UTILITY(U,$J,358.3,58742,1,4,0)
+6 ;;=4^L71.9
+7 ;;^UTILITY(U,$J,358.3,58742,2)
+8 ;;=^5009276
+9 ;;^UTILITY(U,$J,358.3,58743,0)
+10 ;;=L71.8^^272^2912^18
+11 ;;^UTILITY(U,$J,358.3,58743,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,58743,1,3,0)
+14 ;;=3^Rosacea NEC
+15 ;;^UTILITY(U,$J,358.3,58743,1,4,0)
+16 ;;=4^L71.8
+17 ;;^UTILITY(U,$J,358.3,58743,2)
+18 ;;=^5009275
+19 ;;^UTILITY(U,$J,358.3,58744,0)
+20 ;;=L71.1^^272^2912^17
+21 ;;^UTILITY(U,$J,358.3,58744,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,58744,1,3,0)
+24 ;;=3^Rhinophyma
+25 ;;^UTILITY(U,$J,358.3,58744,1,4,0)
+26 ;;=4^L71.1
+27 ;;^UTILITY(U,$J,358.3,58744,2)
+28 ;;=^106083
+29 ;;^UTILITY(U,$J,358.3,58745,0)
+30 ;;=S05.31XA^^272^2912^13
+31 ;;^UTILITY(U,$J,358.3,58745,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,58745,1,3,0)
+34 ;;=3^Ocular Laceration Right Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
+35 ;;^UTILITY(U,$J,358.3,58745,1,4,0)
+36 ;;=4^S05.31XA
+37 ;;^UTILITY(U,$J,358.3,58745,2)
+38 ;;=^5020606
+39 ;;^UTILITY(U,$J,358.3,58746,0)
+40 ;;=S05.32XA^^272^2912^12
+41 ;;^UTILITY(U,$J,358.3,58746,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,58746,1,3,0)
+44 ;;=3^Ocular Laceration Left Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
+45 ;;^UTILITY(U,$J,358.3,58746,1,4,0)
+46 ;;=4^S05.32XA
+47 ;;^UTILITY(U,$J,358.3,58746,2)
+48 ;;=^5020609
+49 ;;^UTILITY(U,$J,358.3,58747,0)
+50 ;;=Z21.^^272^2912^2
+51 ;;^UTILITY(U,$J,358.3,58747,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,58747,1,3,0)
+54 ;;=3^Asymptomatic HIV Infection Status
+55 ;;^UTILITY(U,$J,358.3,58747,1,4,0)
+56 ;;=4^Z21.
+57 ;;^UTILITY(U,$J,358.3,58747,2)
+58 ;;=^5062777
+59 ;;^UTILITY(U,$J,358.3,58748,0)
+60 ;;=Z83.511^^272^2912^6
+61 ;;^UTILITY(U,$J,358.3,58748,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,58748,1,3,0)
+64 ;;=3^Family Hx of Glaucoma
+65 ;;^UTILITY(U,$J,358.3,58748,1,4,0)
+66 ;;=4^Z83.511
+67 ;;^UTILITY(U,$J,358.3,58748,2)
+68 ;;=^5063382
+69 ;;^UTILITY(U,$J,358.3,58749,0)
+70 ;;=Z83.518^^272^2912^5
+71 ;;^UTILITY(U,$J,358.3,58749,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,58749,1,3,0)
+74 ;;=3^Family Hx of Eye Disorder NEC
+75 ;;^UTILITY(U,$J,358.3,58749,1,4,0)
+76 ;;=4^Z83.518
+77 ;;^UTILITY(U,$J,358.3,58749,2)
+78 ;;=^5063383
+79 ;;^UTILITY(U,$J,358.3,58750,0)
+80 ;;=Z79.899^^272^2912^10
+81 ;;^UTILITY(U,$J,358.3,58750,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,58750,1,3,0)
+84 ;;=3^Long Term Current Drug Therapy NEC
+85 ;;^UTILITY(U,$J,358.3,58750,1,4,0)
+86 ;;=4^Z79.899
+87 ;;^UTILITY(U,$J,358.3,58750,2)
+88 ;;=^5063343
+89 ;;^UTILITY(U,$J,358.3,58751,0)
+90 ;;=Z01.00^^272^2912^4
+91 ;;^UTILITY(U,$J,358.3,58751,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,58751,1,3,0)
+94 ;;=3^Eye/Vision Exam w/o Abnormal Findings
+95 ;;^UTILITY(U,$J,358.3,58751,1,4,0)
+96 ;;=4^Z01.00
+97 ;;^UTILITY(U,$J,358.3,58751,2)
+98 ;;=^5062612
+99 ;;^UTILITY(U,$J,358.3,58752,0)
+100 ;;=Z01.01^^272^2912^3
+101 ;;^UTILITY(U,$J,358.3,58752,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,58752,1,3,0)
+104 ;;=3^Eye/Vision Exam w/ Abnormal Findings
+105 ;;^UTILITY(U,$J,358.3,58752,1,4,0)
+106 ;;=4^Z01.01
+107 ;;^UTILITY(U,$J,358.3,58752,2)
+108 ;;=^5062613
+109 ;;^UTILITY(U,$J,358.3,58753,0)
+110 ;;=E05.90^^272^2912^21
+111 ;;^UTILITY(U,$J,358.3,58753,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,58753,1,3,0)
+114 ;;=3^Thyrotoxicosis,Unspec
+115 ;;^UTILITY(U,$J,358.3,58753,1,4,0)
+116 ;;=4^E05.90
+117 ;;^UTILITY(U,$J,358.3,58753,2)
+118 ;;=^5002492
